Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 675

1.

ASGO 5th International Workshop on Gynecologic Oncology.

Son JH, Chang SJ, Ryu HS.

J Gynecol Oncol. 2018 Nov;29(6):e101. doi: 10.3802/jgo.2018.29.e101. No abstract available.

2.

Survival in clinical stage I endometrial cancer with single vs. multiple positive pelvic nodes: results of a multi-institutional Italian study.

Uccella S, Falcone F, Greggi S, Fanfani F, De Iaco P, Corrado G, Ceccaroni M, Mandato VD, Bogliolo S, Casarin J, Monterossi G, Pinelli C, Mangili G, Cormio G, Roviglione G, Bergamini A, Pesci A, Frigerio L, Uccella S, Vizza E, Scambia G, Ghezzi F.

J Gynecol Oncol. 2018 Nov;29(6):e100. doi: 10.3802/jgo.2018.29.e100.

3.

Upregulation of long non-coding RNA XIST has anticancer effects on epithelial ovarian cancer cells through inverse downregulation of hsa-miR-214-3p.

Wang C, Qi S, Xie C, Li C, Wang P, Liu D.

J Gynecol Oncol. 2018 Nov;29(6):e99. doi: 10.3802/jgo.2018.29.e99.

5.

Postoperative chemoradiotherapy versus radiotherapy alone for elderly cervical cancer patients with positive margins, lymph nodes, or parametrial invasion.

Cushman TR, Haque W, Menon H, Rusthoven CG, Butler EB, Teh BS, Verma V.

J Gynecol Oncol. 2018 Nov;29(6):e97. doi: 10.3802/jgo.2018.29.e97.

6.
7.
8.

Current landscape and future perspective of sentinel node mapping in endometrial cancer.

Bogani G, Raspagliesi F, Leone Roberti Maggiore U, Mariani A.

J Gynecol Oncol. 2018 Nov;29(6):e94. doi: 10.3802/jgo.2018.29.e94. Review.

9.

Checkpoint-inhibition in ovarian cancer: rising star or just a dream?

Pietzner K, Nasser S, Alavi S, Darb-Esfahani S, Passler M, Muallem MZ, Sehouli J.

J Gynecol Oncol. 2018 Nov;29(6):e93. doi: 10.3802/jgo.2018.29.e93. Review.

10.

Effect of the pulmonary recruitment maneuver on pain after laparoscopic gynecological oncologic surgery: a prospective randomized trial.

Güngördük K, Aşıcıoğlu O, Özdemir İA.

J Gynecol Oncol. 2018 Nov;29(6):e92. doi: 10.3802/jgo.2018.29.e92.

11.

Association of tumor differentiation grade and survival of women with squamous cell carcinoma of the uterine cervix.

Matsuo K, Mandelbaum RS, Machida H, Purushotham S, Grubbs BH, Roman LD, Wright JD.

J Gynecol Oncol. 2018 Nov;29(6):e91. doi: 10.3802/jgo.2018.29.e91.

12.

BRCA1/2 mutations, including large genomic rearrangements, among unselected ovarian cancer patients in Korea.

Kim DH, Cho CH, Kwon SY, Ryoo NH, Jeon DS, Lee W, Ha JS.

J Gynecol Oncol. 2018 Nov;29(6):e90. doi: 10.3802/jgo.2018.29.e90.

13.
14.

Clinical utility of CA-125 in the management of uterine carcinosarcoma.

Matsuo K, Ross MS, Yunokawa M, Johnson MS, Machida H, Omatsu K, Klobocista MM, Im DD, Satoh S, Baba T, Ikeda Y, Bush SH, Hasegawa K, Blake EA, Takekuma M, Shida M, Nishimura M, Adachi S, Pejovic T, Takeuchi S, Yokoyama T, Ueda Y, Iwasaki K, Miyake TM, Yanai S, Nagano T, Takano T, Shahzad MM, Ueland FR, Kelley JL, Roman LD.

J Gynecol Oncol. 2018 Nov;29(6):e88. doi: 10.3802/jgo.2018.29.e88. No abstract available.

15.

Robotic lower pelvic port placement for optimal upper paraaortic lymph node dissection.

Paek J, Kang E, Lim PC.

J Gynecol Oncol. 2018 Nov;29(6):e87. doi: 10.3802/jgo.2018.29.e87.

16.

Trachelectomy for stage IB1 cervical cancer with tumor size >2 cm: trends and characteristics in the United States.

Matsuo K, Machida H, Mandelbaum RS, Mikami M, Enomoto T, Roman LD, Wright JD.

J Gynecol Oncol. 2018 Nov;29(6):e85. doi: 10.3802/jgo.2018.29.e85. No abstract available.

17.

Quality indicators for cervical cancer care in Japan.

Watanabe T, Mikami M, Katabuchi H, Kato S, Kaneuchi M, Takahashi M, Nakai H, Nagase S, Niikura H, Mandai M, Hirashima Y, Yanai H, Yamagami W, Kamitani S, Higashi T.

J Gynecol Oncol. 2018 Nov;29(6):e83. doi: 10.3802/jgo.2018.29.e83.

18.

Impact of beta blockers on survival outcomes in ovarian cancer: a nationwide population-based cohort study.

Baek MH, Kim DY, Kim SO, Kim YJ, Park YH.

J Gynecol Oncol. 2018 Nov;29(6):e82. doi: 10.3802/jgo.2018.29.e82.

19.

Treatment outcomes of high-dose-rate intracavitary brachytherapy for cervical cancer: a comparison of Ir-192 versus Co-60 sources.

Tantivatana T, Rongsriyam K.

J Gynecol Oncol. 2018 Sep;29(5):e86. doi: 10.3802/jgo.2018.29.e86.

20.

Lynch syndrome - Muir-Torre variant: implication in gynecologic oncology.

Bogani G, Leone Roberti Maggiore U, Raspagliesi F.

J Gynecol Oncol. 2018 Sep;29(5):e84. doi: 10.3802/jgo.2018.29.e84. No abstract available.

Supplemental Content

Loading ...
Support Center